Decades-old HIV charity's fear over future funding
Positively UK, which has supported people with HIV for almost 40 years, has already closed its pan-London gay men's peer support group after being unable to secure funding for its future.
Silvia Petretti, CEO said: "The support we give is very emotional. However, most of the time we have very short-term funding. From one year to another, we never know if we're going to be around."
The government said it was "fully committed" to ending new HIV transmissions in England by 2030 and that its upcoming HIV Action Plan would focus on prevention and testing, as well as living well with HIV.
According to the National Aids Trust, 2023 was the highest year for people receiving HIV care, with 107,949 treated - an increase of 27% across the last 10 years.
Ms Petretti said: "HIV is not over. We have treatment for HIV, but we don't have a treatment for stigma yet."
"Positively UK has existed since the 1980s," she added. "We're going to be 40 next year and I am worried that our services may not be there for people in the future because of the lack of funding.
"We finished the year in the deficit and one of the most important services for us, the gay men's project, had to stop. In the past two years we applied to nine different funds and we couldn't secure any funding for the project."
Phil Dehany started attending the support group four years after he was diagnosed with HIV in 2016.
"I live by myself here in London and it can be lonely," he said. "Those opportunities to meet up with people once a month were a lifeline.
"I would go as often as I could, and it's one of those things that you don't miss until it's gone, and I wish now that I'd gone a lot more often."
"It was really sad when the project came to an end - straight away you've just lost that connection to that community."
Mr Dehany said he now uses a range of other voluntary organisations, but fears that if funding struggles continue, those who need support, including elderly people living with HIV, will suffer.
'Nothing to replace that service'
The voluntary and community sectors that offer support services for people living with HIV have faced big cuts in the last decade, the National Aids Trust said.
A report by the charity found 71% of London's HIV voluntary, community, and social enterprise organisations had to either reduce staff numbers, close services, merge with other organisations or use cash reserves to cover operating costs in the last three years.
Some 40% were concerned about their ability to deliver services over the next three years.
Robbie Currie, CEO of the National Aids Trust, said: "There's a funding crisis going on within the sector across the UK.
"Statutory services have been massively reduced. It has really impacted on service provision. Services are either being cut completely or they are being reduced."
Of Positively UK, he said: "There's just nothing to replace that service."
The government recently pledged to end all new HIV diagnoses by 2030.
Ms Petretti said: "The government wants the UK to reach zero transmissions by 2030, but if people are not supported to stay well, we will not reach this goal."
In June, the Local Government Association warned that sexual health services in England were grappling with "unprecedented pressure" and urged the government to carve out a 10-year strategy and invest more to deliver "expert, timely care".
A spokesperson for the Department of Health and Social Care said its 10-year health plan focused on how local government could improve services for sexual health by making better use of funding and working more closely with the NHS.
They added: "We are fully committed to ending new HIV transmissions in England by 2030 and our upcoming HIV Action Plan will focus not just on prevention and testing, but also on helping people live well with HIV."
They said more than £6m had been invested in the National HIV Prevention Programme and £27m of funding was announced in December.
Additional reporting by Josef Steen, Local Democracy Reporting Service.
Listen to the best of BBC Radio London on Sounds and follow BBC London on Facebook, X and Instagram. Send your story ideas to hello.bbclondon@bbc.co.uk
Sexual health clinic axed despite STI hotspot
Battle against HIV in London 'needs scaling up'
'I was told I had between three and nine months to live'
Related internet links
Positively UK
Government guidance on commissioning local HIV sexual and reproductive health services

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 minutes ago
- Yahoo
Hims & Hers Health Inc (HIMS) Q2 2025 Earnings Call Highlights: Robust Revenue Growth Amid ...
Revenue: $545 million, a 73% year-over-year increase. Adjusted EBITDA Margin: Over 15%. Subscribers: Increased by 73,000 quarter over quarter to over 2.4 million, a 31% year-over-year growth rate. Monthly Average Revenue per Subscriber: Declined quarter over quarter to $74 from $84. Gross Margin: Expanded 3 points quarter over quarter to 76%. Cash and Short-term Investments: Over $1.1 billion at the end of the second quarter. Free Cash Flow: Negative $69 million for the second quarter. Third Quarter Revenue Guidance: Expected between $570 million to $590 million. Full Year Revenue Guidance: Expected between $2.3 billion and $2.4 billion. Full Year Adjusted EBITDA Guidance: Expected between $295 million to $335 million. Warning! GuruFocus has detected 5 Warning Sign with HIMS. Release Date: August 04, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Hims & Hers Health Inc (NYSE:HIMS) reported a 73% year-over-year revenue growth to $545 million in Q2 2025, with an adjusted EBITDA margin exceeding 15%. The company is expanding its platform with new specialties, including hormonal health, which is expected to address significant health issues for both men and women. Hims & Hers Health Inc (NYSE:HIMS) successfully acquired ZAVA, enhancing its presence in the UK and establishing a foundation for further expansion in Europe and Canada. The company is investing in AI and technology to enhance personalized care, aiming to provide 24/7 support and improve patient engagement. Hims & Hers Health Inc (NYSE:HIMS) plans to offer lab testing as a standalone service, which is expected to empower customers with better health insights and proactive health management. Negative Points The company faced headwinds from off-boarding GLP-1 subscribers on commercially available dosages, impacting revenue recognition. There is a decline in the on-demand sexual health subscriber base, which is expected to continue affecting revenue in the short term. Hims & Hers Health Inc (NYSE:HIMS) reported a negative free cash flow of $69 million in Q2 2025 due to significant investments in inventory and working capital. The transition towards more premium daily offerings in the sexual health segment is causing temporary revenue declines. The company anticipates increased marketing and technology investments, which may pressure margins in the near term. Q & A Highlights Q: Why was now the right time to expand internationally, and what made ZAVA the right company to acquire? A: Andrew Dudum, CEO, explained that the acquisition of ZAVA is a strategic move to replicate Hims & Hers' personalized, high-touch, affordable precision medicine model in key international markets. ZAVA's ability to scale in unique regulatory environments was a key factor in the acquisition. The international market is seen as a focused effort, with a multibillion-dollar revenue opportunity in a few key markets. Q: How does the launch of at-home lab testing improve the business and support the broader mission of Hims & Hers? A: Andrew Dudum, CEO, emphasized that at-home lab testing is foundational for transitioning healthcare from treatment to prevention. It simplifies necessary tests, makes them affordable, and educates patients on optimal health metrics. This initiative is expected to open membership opportunities similar to Amazon or Costco, focusing on preventative health. Q: Can you provide insights into the core business dynamics and expectations for Q3, especially regarding the personalized GLP-1 offering? A: Oluyemi Okupe, CFO, noted material headwinds in the GLP-1 segment due to off-boarding commercially available dosages. The core business is experiencing a drag from the sexual health on-demand segment, but specialties like dermatology and weight loss are growing robustly. The transition to daily offerings in sexual health is expected to improve retention and customer lifetime value. Q: What are the expectations for the Canadian expansion and the impact of generic semaglutide pricing? A: Andrew Dudum, CEO, stated that the Canadian expansion will leverage ZAVA's expertise, with offerings under the Hims & Hers brand. The generic semaglutide is expected to be priced significantly lower than branded options, unlocking substantial market access in Canada, where a large portion of the population is affected by weight issues. Q: How is the Hers business performing, and what are the key growth drivers? A: Oluyemi Okupe, CFO, reported robust growth in the Hers business, driven by dermatology, weight loss, and mental health offerings. The upcoming launch of hormonal support for menopause is expected to further catalyze growth. Q: What is the approach to AI investments, and what impact is expected on the business? A: Andrew Dudum, CEO, highlighted a strategy focused on immediate, tactical improvements through AI. The platform's extensive patient interactions allow for rapid deployment of AI use cases, aiming to enhance efficiency and engagement across the provider, patient, and pharmacist interfaces within 3 to 6 months. Q: Can you discuss the marketing strategy and patient acquisition costs for the second half of the year? A: Oluyemi Okupe, CFO, stated that marketing investments will be robust but adhere to a capital allocation framework with a payback period of less than a year. The focus will be on specialty-specific investments and talent acquisition to support new specialties and international expansion. Q: What are the expectations for inventory levels and supply chain management? A: Oluyemi Okupe, CFO, explained that inventory levels increased to ensure a durable supply for new specialties and to leverage the strong balance sheet amid global uncertainties. This is seen as an anomaly, with future inventory adjustments expected to stabilize. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio


Medscape
4 minutes ago
- Medscape
High Lp(a) Signals Risk Beyond The Coronaries
TOPLINE: Elevated levels of lipoprotein(a) [Lp(a)] were associated with significantly increased risks for incident peripheral artery disease and carotid artery stenosis. Among patients with peripheral artery disease, those with high levels of Lp(a) (≥ 150 nmol/L) had a high risk of progressing to major adverse limb events. METHODOLOGY: Despite lifestyle interventions and therapies for lowering levels of cholesterol, a residual risk for major atherosclerotic complication persists. Researchers analyzed data from a large prospective biobank (2006-2010) to investigate whether baseline levels of Lp(a) predict the risk for onset and progression of extracoronary atherosclerotic vascular disease — a combination of peripheral artery disease and carotid artery stenosis. The UK biobank data included 460,544 individuals (average age at enrollment, 57 years; 54.2% men; 94.9% European) and followed them for a median duration of 13.6 years. Data on baseline serum levels of Lp(a) were retrieved, with levels ≥ 150 nmol/L (about 70 mg/dL) defined as high. The analysis assessed the incidence of peripheral artery disease and carotid artery stenosis and the progression to both the first major adverse limb event and first stroke. TAKEAWAY: Individuals with high levels of Lp(a) were older and more often men than those with normal levels of Lp(a) (P < .001 for both). Each 75-nmol/L (35 mg/dL) increase in levels of Lp(a) was associated with a 1.18-fold elevated risk for incident peripheral artery disease and a 1.17-fold increased risk for incident carotid artery stenosis (P < .0001 for both). Among patients with peripheral artery disease, those with high levels of Lp(a) had a 1.6-fold higher risk of developing major adverse limb events than those with normal levels of Lp(a) (P = .004). IN PRACTICE: 'Participants with established atherosclerotic vascular disease and elevated Lp(a) concentrations may represent the ideal group to benefit from targeted preventive interventions,' the researchers noted. '[The study's] findings make a strong case to explore the effect of therapies to lower Lp(a) in participants with PAD [peripheral artery disease] and carotid stenosis towards the goal of slowing disease progression and reducing major complications of amputation and stroke,' they added. SOURCE: This study was led by Tiffany R. Bellomo, MD, of Broad Institute of Harvard and MIT, Cambridge, Massachusetts. It was published online on July 28, 2025, in Circulation. LIMITATIONS: Measuring Lp(a) using immunoassays may be inaccurate for individuals with large Lp(a) isoforms. This study lacked measurement of ankle-brachial index to define peripheral arterial disease. The analysis may not have accounted for all potential confounding factors. DISCLOSURES: This study received grants from the National Heart, Lung, and Blood Institute and the National Human Genome Research Institute. One author reported receiving research grants and personal fees from several pharmaceutical and healthcare companies and holding equity in multiple healthcare data and biotech firms. The same author reported spousal employment at a pharmaceutical company. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
33 minutes ago
- Yahoo
Man suffers 'multiple injuries' after tripping on Keswick fell
A man who suffered 'multiple injuries' after tripping on Catbells near Keswick, has been rescued. Keswick Mountain Rescue Team (MRT) were deployed on Saturday, August 2 to assist a 63-year-old man who had tripped on the 'short scramble section' on Skelgill Bank, Catbells. Due to the trip, the man has suuffered cuts and abrasions and sustained possible rib and spinal damage. After arriving at the scene, the man was assessed by Keswick MRT and stretchered down to an awaiting North West Ambulance Service (NWAS) crew. Writing on social media, Keswick MRT said: "A 63-year-old man tripped on the short scramble section on Skelgill Bank, Catbells, sustaining cuts and abrasions to his head and bashing his shoulder and elbow. "With multiple injuries and the possibility of rib and spinal damage the man was given pain relief and packaged in a vacuum mattress before being stretchered down to an awaiting ambulance." The rescue operation included 11 team members from Keswick MRT and lasted nearly three hours.